Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 2003-2013

  Karantanos, Theodoros ^a   Tanimoto, Ryuta ^b   Edamura, Kohei ^b   Hirayama, Takahiro ^c   Yang, Guang ^a   Golstov, Alexei A ^a   Wang, Jianxiang ^a   Kurosaka, Shinji ^c   Park, Sanghee ^a   Thompson, Timothy C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GLIPR1; prostate cancer; protein therapy

Indexed keywords

GLIPR1; PROSTATE CANCER; PROTEIN THERAPY;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CLATHRIN; ENDOCYTOSIS; ENDOSOMES; HUMANS; LYSOSOMES; MALE; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES; SEQUENCE DELETION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893739012     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28529     Document Type: Article

References (26)

1. Marciscano AE, Hardee ME, Sanfilippo N,. Management of high-risk localized prostate cancer. Adv Urol 2012; 2012: 641689.
2. Dayyani F, Gallick GE, Logothetis CJ, et al. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011; 103: 1665-75.
3. Skigeta K, Miura Y, Naito Y, et al. Cabazitaxel for castration-resistant prostate cancer. Lancet 2011; 121: 122-3.
4. Ren C, Li L, Goltsov AA, et al. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 2002; 10: 3345-57. (Pubitemid 34453976)
5. Ren C, Li L, Yang G, et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 2004; 3: 969-76. (Pubitemid 38176899)
6. Xiao YH, Li XH, Tan T, et al. Identification of GLIPR1 tumor suppressor as methylation-silenced gene in acute myeloid leukemia by microarray analysis. J Cancer Res Clin Oncol 2011; 12: 1831-40.
7. Chilukamarri L, Hancock AL, Malik S, et al. Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. Neoplasia 2007; 11: 970-8. (Pubitemid 350086442)
8. Li L, Abdel Fattah E, Cao G, et al. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 2008; 2: 434-43. (Pubitemid 351380069)
9. Satoh T, Timme TL, Saika T, et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 2003; 2: 91-101. (Pubitemid 36418814)
10. Sonpavde G, Thompson TC, Jain RK, et al. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 2011; 22: 7174-82.
11. Naruishi K, Timme TL, Kusaka N, et al. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 2006; 7: 658-63. (Pubitemid 44264470)
12. Li L, Ren C, Yang G, et al. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res 2011; 24: 7694-704.
13. Li L, Yang G, Ren C, et al. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 2013; 7: 484-96.
14. Tabata K, Kurosaka S, Watanabe M, et al. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 2011; 10: 969-78.
15. Salacinski PR, McLean C, Sykes JE, et al. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1, 3, 4, 6,-tetracholoro-3 alpha, 6 alpha-diphenyl glycoluril (lodogen). Anal Biochem 1981; 117: 136-46. (Pubitemid 12211794)
16. Gartel AL, Serfas MS, Gartel M, et al. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res 1996; 227: 171-81. (Pubitemid 26320157)
17. Doherty GJ, McMahon HT,. Mechanisms of endocytosis. Annu Rev Biochem 2009; 78: 857-902.
18. McMahon HT, Boucrot E,. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 2011; 8: 517-33.
19. Liu T, Daniels CK, Cao S,. Comprehensive review on the HSC70 functions, interactions with related molecules and involvement in clinical diseases and therapeutic potential. Pharmacol Ther 2012; 3: 354-74.
20. Newmyer SL, Schmid SL,. Dominant-interfering Hsc70 mutants disrupt multiple stages of the clathrin-coated vesicle cycle in vivo. J Cell Biol 2001; 3: 607-20. (Pubitemid 34280242)
21. Goldfarb SB, Kashlan OB, Watkins JN, et al. Differential effects of Hsc70 and Hsp70 on the intracellular trafficking and functional expression of epithelial sodium channels. Proc Natl Acad Sci USA 2006; 103: 5817.
22. Terlecky SR, Chiang HL, Olson TS, et al. Protein and peptide binding and stimulation of in vitro lysosomal proteolysis by the 73-kDa heat shock cognate protein. J Biol Chem 1992; 13: 9202-9.
23. Benassi B, Fanciulli M, Fiorentino F, et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006; 4: 509-19. (Pubitemid 43228006)
24. Watson J,. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 2013; 1: 120144.
25. Shiota M, Song Y, Takeuchi A, et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 2012; 187: 707-14.
26. Bernard D, Pourtier-Manzanedo A, Gil J, et al. Myc confers to androgen-independent prostate cancer cell growth. J Clin Invest 2003; 112: 1724-31. (Pubitemid 38063730)